410
Participants
Start Date
November 14, 2024
Primary Completion Date
May 31, 2028
Study Completion Date
May 31, 2028
Phase I Arm A
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Phase I Arm B
Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
RECRUITING
St Vincent's Hospital Sydney, Darlinghurst
RECRUITING
Peter Maccallum Cancer Centre, Parkville
RECRUITING
Montefiore Einstein Cancer Center, The Bronx
RECRUITING
Seoul National University Bundang Hospital, Seongnam
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC, Madrid
RECRUITING
Florida Cancer Specialist-Lake Mary, Lake Mary
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Hospital Universitario Virgen del Rocio - PPDS, Seville
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
University of Illinois, Chicago
RECRUITING
Sarah Cannon Research Institute at HealthONE, Denver
RECRUITING
National University Hospital, Singapore
RECRUITING
National Cancer Centre, Singapore
RECRUITING
Rambam Health Care Campus, Haifa
RECRUITING
The Chaim Sheba Medical Center, Ramat Gan
RECRUITING
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv
RECRUITING
Hadassah University Hospital - Ein Kerem, Jerusalem
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
START - Midwest - EDOS, Grand Rapids
RECRUITING
Mary Crowley Medical Research Center, Dallas
RECRUITING
Abramson Cancer Center;Univ of Pennsylvania, Philadelphia
RECRUITING
British Columbia Cancer Agency, Vancouver
RECRUITING
Princess Margaret Cancer Centre, Toronto
RECRUITING
Sir Mortimer B Davis Jewish General Hospital, Montreal
RECRUITING
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON, Barcelona
RECRUITING
Western General Hospital;Edinburgh Cancer Center, Edinburgh
RECRUITING
The Christie, Manchester
Lead Sponsor
Genentech, Inc.
INDUSTRY